NCT05438810: This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer. |
|
|
| Recruiting | 3 | 312 | RoW | FCN-437c,Fulvestrant,Goserelin acetate, Placebo,Fulvestrant,Goserelin acetate | Ahon Pharmaceutical Co., Ltd. | Advanced Breast Cancer, Female Breast Cancer | 02/24 | 05/24 | | |
NCT05439499: This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer. |
|
|
| Recruiting | 3 | 434 | RoW | FCN-437c, Letrozole or anastrozole, Goserelin acetate, Placebo, Letrozole or anastrozole, Goserelin acetate | Ahon Pharmaceutical Co., Ltd. | Advanced Breast Cancer, Female Breast Cancer | 09/24 | 03/25 | | |
